Alembic Pharmaceuticals receives final US FDA approval for Bromfenac Solution, 0.07 per cent

Bromfenac Ophthalmic Solution 0.07 per cent is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Mumbai: Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Prolensa Ophthalmic Solution, 0.07 per cent, of Bausch & Lomb Incorporated (Bausch).

Bromfenac Ophthalmic Solution 0.07 per cent is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Refer to the label for a detailed indication.

Bromfenac Ophthalmic Solution, 0.07 per cent has an estimated market size of $168 million for twelve months ending March 2024, according to IQVIA.

News Source:

https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/alembic-pharmaceuticals-receives-final-us-fda-approval-for-bromfenac-ophthalmic-solution-0-07-per-cent/111608174